White Paper

High Viscosity Formulations: Developing An Effective Primary Drug Container System

Source: SMC Ltd.

By Susanna White, Oval Medical Technologies

iStock-1292778196-autoinjector

The past few years have seen a significant increase in the number of high viscosity (HV) formulations (100 – 1000 cP) being developed. Innovations in the field of biologics, as well as an increased interest in the use of Long Acting Injectables (LAIs), mean that autoinjector developers are constantly being challenged by new formulations with increasingly complex flow behaviours. These new formulations can provide a great number of benefits for patients and health care providers through access to cutting edge therapies and by reducing both dosing frequency and delivered volume. However unless they can be delivered in a patient-orientated manner, these benefits cannot be fully realised. There are a number of steps that autoinjector developers can take to meet the challenges posed by such formulations. This poster will focus on some of the techniques that Oval Medical Technologies has used to develop the ArQ™-Bios high viscosity platform (Figure 1).

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: